Search Results

Total 50 documents found.

•  

• ANNUALREPORT2009TakedaPharmaceuticalCompanyLimited Annual Report 2009 Our Contribution to Financial and Social Responsibility Editorial Policy Takeda integrates its annual report and CSR report into a single publication with a mind to give readers a complete understanding of how our business operations are guided by Takeda-ism and other elements of our corporate philosophy. Contributes to the Health of Individuals Takeda has been supplying pharmaceuticals for more than 220 years while never forgetting the importance of protecting and preserving life. Over the years, we have developed a strong commitment to the highest ethical standards and strong sense of mission. As our operations became global in scale, demands concerning corporate social responsibility (CSR) increased. We believe that developing superior pharmaceutical products in accordance with the principles of Takeda-ism is the essence of CSR for the Takeda Group. Due to this strong link between our business activities and CSR, since fiscal 2006, Take

• Annual Report 2009 Based on Takeda-ism Relationship with Our Stakeholders CSR Data Book Annual Report 2009 1 CSR Data Book 2 12 14 16 18 20 22 24 26 Relationship with Society Relationship with Environment Relationship with Suppliers Relationship with Employees 8 Quality Assurance System 56 Stakeholders' Voices Employees Who Embody the Takeda-ism Ideals 28 30 32 33 34 36 37 38 40 42 43 44 46 48 50 52 54 4 Scope of Reporting Participating in the United Nations Global Compact Annual Report 2009 - Takeda Pharmaceutical Company Limited Table of Contents Editorial Policy Basic Policy on CSR / CSR Promotion Framework / CSR Activities in Fiscal 2009 Feature Feature: Access to Healthcare in Asia (Activities in Asia) Takeda's Corporate Citizenship Activities Activities in the U.S. Activities in France and Germany Activities in Italy and the UK Activities in Japan and Taiwan Activities in the Philippines and Thailand Other Activities Feature: Supply Chain Management Basic Purchasing Policy / Green Procurement and CSR P

• 64 Fundamental Stance regarding the Preservation of Biodiversity Kyoto Herbal Garden The Earth plays host to as many as 30 million species of living things. But this number is falling at an alarming rate. According to the U.N. Millennium Ecosystem Assessment, which was completed in 2005, the current rate of extinctions is about 1,000 times greater than the extinction rate in ancient times based on fossil records. Moreover, many scientists believe a further increase of more than 10 times in the extinction rate is inevitable. The U.N. has declared 2010 to be the International Year of Biodiversity. In this year, the 10th Conference of the Parties to the Convention on Biological Diversity (COP10) will take place in Nagoya, Japan. As a company engaged in businesses that protect life, Takeda has a long history of commitment to protecting biodiversity. We have contributed in many ways over the years, particularly through the Kyoto Herbal Garden, which grows many plants that are on the verge of extinction. As a phar

• - 1 - SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Nine Months Results (April 1 to December 31, 2008) for the Fiscal Year Ending March 31, 2009 February 3, 2009 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hirofumi Inoue, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: February 13, 2009 1. Consolidated Financial Results (April 1 to December 31, 2008) for the Fiscal Year Ending March 31, 2009 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( million) change (%) Nine months ended December 31, 2008 1,202,760 239,884 254,578 168,573 Nin

• Date Summary 1-Apr-08 Cell Genesys and Takeda Announce Global Alliance for the Development and Commercialization of GVAX Immunotherapy for Prostate Cancer 1-Apr-08 New Data Showed ACTOS (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients with Type 2 Diabetes Data expands body of evidence in high risk population using IVUS,a unique marker for coronary atherosclerosis 1-Apr-08 Launch of Takeda Bio Development Center Limited 1-Apr-08 Transfer of Shares of Hitachi Inspharma, Ltd. from Takeda to Hitachi 4-Apr-08 Takeda Wins Definitive Decision in Patent Infringement Litigation on Appeal against an ANDA Filer for Generic ACTOS 10-Apr-08 Takeda to Acquire Millennium for Us$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion -- Acquisition Accelerates Takeda's Vision of Becoming a Global Leader in Oncology -- 30-Apr-08 Sucampo Pharmaceuticals Obtains FDA Approval for AMITIZA for the Treatment of Irritable Bowel Syndrome with Constipation in Adult Women 9-May-08 Takeda

• 17 X. Pipeline Development Activities ■ New compounds ■ Additional indications/new formulations ■ Characteristics of projects ■ Other alliance projects ■ Clinical study protocol summaries ■ Outcome studies Research Activities ■ Main joint research activities 18 Development activities ■ New Compounds Development code Drug Class (administration route) Indications Stage In-house/ In-license SYR-322 DPP-4 inhibitor (oral) Diabetes mellitus Diabetes mellitus (Fixed-dose combination with ACTOS) US Jpn EU US EU Filed (Dec 07) Filed (Sep 08) P-III Filed (Sep 08) P-III In-house TAK-390MR Proton pump inhibitor (oral) Erosive esophagitis (healing and maintenance) and non-erosive gastro-esophageal reflux disease US Jpn Filed (Dec 07) P-II In-house TAK-375 MT1/MT2 receptor agonist (oral) Insomnia Circadian rhythm sleep disorder (CRSD) EU Jpn US P-III *Re-submission of a MAA is under consideration Filed (Feb 08) P-II In-house Vectibix TM Fully

• - 1 - Consolidated Financial Statements for the Fiscal Year Ended March 31, 2009 May 11, 2009 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya (First Section of each), 1-1, Doshomachi 4-chome Fukuoka, Sapporo Chuo-ku, Osaka 540-8645, Japan Code number: 4502 URL: http://www.takeda.co.jp/ Representative: Yasuchika Hasegawa, President Contact: Hirofumi Inoue, General Manager of Corporate Communications Department Telephone: +81-3-3278-2037 Scheduled date of annual general meeting of shareholders: June 25, 2009 Scheduled date of securities report submission: June 25, 2009 Scheduled date of dividend payment commencement: June 26, 2009 1. Consolidated Results for Fiscal 2008 (April 1, 2008-March 31, 2009) (1) Sales and Income (All amounts are rounded to the nearest million yen) (Percentage figures represent changes from same period o

• Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2008 - 4 - [Qualitative Information and Financial Statements] 1. Results of Operations (1) Analysis of Operation Results 1) Introduction In order to realize Takeda's goal of establishing itself as a "global pharmaceutical company", which was set as a target in the 20062010 Medium-term Plan, the Company has been working on various strategies. To achieve this goal, the Company completed a meaningful acquisition and restructuring last year. Firstly, we evenly separated the value of TAP Pharmaceutical Products Inc. ("TAP")a joint venture between Takeda America Holdings, Inc. ("TAH") and Abbott Laboratories ("Abbott") of the U.S.into two companies in April 2008. As part of this company separation, TAP acquired assets related to the already marketed product Prevacid, as well as those related to TAK-390MR (a drug for gastroesophageal reflux disease) and TMX-67 (a drug for hyperuricemia for patients with chronic gout, discovere

• 22 Europe R&D in In order to help you further deeply understood Takeda's "current" and "future" globalization, a special feature in terms of our European operations is introduced in this section over six pages. Takeda has responded to industry trends, namely the socalled "integration of the global pharmaceutical market," from an early stage, since advancing to establish structures of R&D and the Japan-U.S.-Europe tripolar marketing functions. In Europe, we have been promoting following various approaches to establish our operating base. In fiscal 2006, we launched Takeda Cambridge Limited (TCB), which is anticipated to play a role in the global R&D network, as well as Takeda Pharmaceuticals Europe Limited (TPEU), which supervises the overall sales activities of Takeda's six subsidiaries in Europe. In addition, we also have been proactively participating in CSR activities, aiming to make further contributions to our stakeholders. Takeda Pharmaceuticals Europe Limited (U.K.) Takeda Cambridge Limited Takeda Glo

• 32 Pipeline represents ethical drugs under development, from the start of research to approval/launching. Clinical trials are conducted on humans for drugs for which basic research and nonclinical trials have already been completed. Through the procedures of three-phased clinical trials and following efficacy and safety evaluation, the pipelines are launched onto the market as new drugs after approval by the regulatory authorities. Implemented for a small group of healthy adults in order to evaluate safety and ADME (Absorption, Distribution, Metabolism, Excretion) of the drug. R&D Pipeline SYR-322 is a promising pipeline for the treatment of diabetes, following our core product: Actos. SYR-322 was founded by Takeda San Diego, Inc. (TSD) as a therapeutic agent for Type 2 diabetes, with a DPP-4* inhibitory action. In December 2007, SYR-322 was submitted for a New Drug Application in the U.S. Major Promising Pipelines as Next-Generation Core Products ■Anti-Diabetic Drug: SYR-322 TAK-491 is positioned as a succ

• 82 Consolidated Balance Sheets Takeda Pharmaceutical Company Limited and Subsidiaries Years ended March 31, 2008 and 2007 Millions of yen Thousands of U.S. dollars (Note 1) ASSETS 2008 2007 2008 Current assets: Cash and cash equivalents. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,613,240 1,647,694 $16,132,400 Marketable securities (Note 3). . . . . . . . . . . . . . . . . . . . . . . . . . 45,453 92,342 454,530 Short-term investments. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26,300 59,900 263,000 Notes and accounts receivable Trade notes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15,212 20,695 152,120 Trade accounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 224,537 232,639 2,245,370 Due from affiliates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8,440 8,641 84,400 Allowance for doubtful receivables . . . . . . . . . . . . . . . . . . . . (899) (535) (8,990) Total . . . . . . . . . . . . . .

• 54 Our Basic Stance toward Global Warming Prevention Takeda releases GHG into the air during each stage of our business operations, including the procurement of raw materials, manufacture, distribution and disposal, and hence takes the need to strive to reduce GHG emissions as a member of global society for granted. Takeda organized the energy conservation committee in 1974, following the first major oil shock, and followed subsequently by the steady implementation of energy conservation activities, which have helped reduce GHG emissions for over three decades. Takeda believes that promoting a further approach toward global warming prevention globally, while also sharing such actual achievements and knowhow, will be our challenges in future. Takeda has developed the 9th energy conservation program for the period 2006 - 2010 and our activities toward efficient energy use have been progressing. The 9th energy conservation program sets a target to reduce CO2 emissions by 40 percent (a reduction of 30 percent wi

• ANNUALREPORT2007 Annual Report 2007 Our Contribution to Financial and Social Responsibility TakedaPharmaceuticalCompanyLimited Contributes to The Health of Individuals Worldwide The image in the globe: the molecular representation of ramelteon (Rozerem ), insomnia medication This annual report includes forward-looking statements regarding Takeda's plans, prospects, strategies and accomplishments, etc. These prospects are the result of assessment obtained from information currently available, and since the actual performance could be influenced by various risks and uncertainty, it shall be noted that the course of action could differ substantially from those prospects. Factors that could affect future prospects would include, but are not limited to, economic circumstances surrounding Takeda's domain identity, competitive pressures, relevant laws and regulations, change in the status of product development, exchange rate risk and so on. Precautions Regarding Forward-Looking Statements Aiming to facilitate unde

• 42 Basic Principles on the Environment Give serious consideration to the impact on the environment in every aspect of corporate activities, including R&D, production, distribution, marketing, procurement and clerical works, and make the best efforts to conserve and improve the environment. Conserve energy and other resources, and actively pursue waste minimization and resource recycling. 2. Efficient Utilization of Resources and Minimization of Waste When developing new products and processes, evaluate the impact on the environment in advance, during development, and periodically after commercialization. Consider the entire business cycle from procurement of raw materials and supplies through the use and the final disposal of products to reduce the impact on the global environment. 3. Assessment of Environmental Impact from Products and Manufacturing Processes Develop technologies for environmental protection and improvement, and actively pursue outside technologies when it is beneficial. 4. Development and

• 72 Millions of yen Thousands of U.S. dollars (Note 1) ASSETS 2007 2006 2007 Current assets: Cash and cash equivalents 1,647,694 1,626,235 $13,963,508 Marketable securities (Note 5) 92,342 243,285 782,559 Short-term investments 59,900 507,627 Notes and accounts receivable Trade notes 20,695 21,137 175,381 Trade accounts 232,639 207,887 1,971,517 Due from affiliates 8,641 7,656 73,229 Allowance for doubtful receivables (535) (309) (4,534) Total 261,440 236,371 2,215,593 Inventories (Note 6) 105,307 98,258 892,432 Deferred tax assets (Note 12) 139,223 135,019 1,179,856 Other current assets 51,807 32,802 439,044 Total current assets 2,357,713 2,371,970 19,980,619 Property, plant and equipment (Note 7): Land 62,271 44,853 527,720 Buildings and structures 256,546 247,106 2,174,119 Machinery and equipment 233,693 218,161 1,980,449 Tools and fixtures 63,191 61,888 535,517 Construction in progress 4,987 20,260 42,263 Total 620,688 592,268 5,260,068 Accumulated depreciation (382,242) (376,598) (3,239,339) Net property

• Takeda Pharmaceutical Company Limited Third Quarter ResultsThird Quarter Results for Fiscal 2006for Fiscal 2006 Conference Call January 31, 2007Conference Call January 31, 2007 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited Consolidated ResultsConsolidated Results First Three Quarters of Fiscal 2006First Three Quarters of Fiscal 2006 Hiroshi Takahara Corporate Officer General Manager, Finance & Accounting Department 3 Takeda Pharmaceutical Company Limited 15.0 [32.6] [7.8 -12.74 ] 24.0 4.0 935.2 < > 346.6 418.9 1,003.8 382.8 475.7 68.6 36.2 56.8 7.3 10.5 13.6 < > < > < > < >- 281.1 - 116.1 266.2 139.4 23.3 5.3 20.1 < > < > - Performance Summary First 3QPerformance Summary First 3Q''s 2006s 2006 EPS Net sales Operating income Ordinary income Net income R&D expenses 317.60 304.86 [40.4][Extraordinary income] First3Q's 2005 billion yen <%> First3Q's 2006 billion yen Increase/Decrease billion yen 4 Takeda Pharmaceutical Company Limited on consumer

• 1 Takeda Pharmaceutical Company Limited President Yasuchika Hasegawa November 7, 2006 Management PolicyManagement Policy First half in Fiscal 2006 2 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited 2006-2010 Medium-Term Management Plan Approaches toward lean andApproaches toward lean and solid structuresolid structure 9595--0000 PlanPlan 0101--0505 PlanPlan 〜〜 Growth Toward aGrowth Toward a ""WorldWorld--Class PharmaceuticalClass Pharmaceutical Company with Japanese Origin, as based on TakedaCompany with Japanese Origin, as based on Takeda--ismism""〜〜20062006--20102010 MediumMedium--TermTerm Management PlanManagement Plan New growth stage toward aNew growth stage toward a ""WorldWorld--class pharmaceuticalclass pharmaceutical companycompany"" 3 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited 2006 2010 Medium-Term Management Plan Financial Goals Sales: mid-single digit growth R&D: high-single digit increase Net income: low-single digit growth EPS: more

• 1 Takeda Pharmaceutical Company Limited Kiyoshi Kitazawa Managing Director, General Manager Strategic Product Planning Dept. November 7, 2006 MM PP DD RR AA PP R&D pipeline Update First half in Fiscal 2006 2 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited Core Therapeutic AreasCore Therapeutic Areas Franchise I: Life style-related diseases Franchise II :Oncology & Urology diseases Franchise III:CNS, bone/joint diseases Franchise IV:Gastroenterology diseases 3 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited ○Fixed combination with diuretic (Jpn)TCV-116 ApprovalNDAPhIIIPhIIIndications or formulationsProject ○Diabetes mellitus (US,EU)SYR-322 Combination drug of ACTOS/SU (EU) AD-4833SU (Tandemact) ○Delay in progression of Atherosclerosis (US)AD-4833 ○Combination drug of ACTOS/Metformin XT(US)AD-4833XT ○Impaired Glucose Tolerance (Jpn)AO-128 ○Combination drug of ACTOS/Metformin (EU) AD-4833MET (Competact) ○Combination drug of ACTOS/SU (US) AD-4833SU (Du

• [Qualitative Information, Financial Statements and Other Information] 1. Results of Operations (1) Analysis of Results of Operations 1) Overview of Results In April 2006 the Japanese government carried out a special drug price reduction and revision of price calculation for branded drugs for which substitute generic drugs were available, in addition to the ordinary reduction of National Health Insurance (NHI) drug prices. Furthermore, specific measures to encourage the use of generic drugs began to be implemented. In this severe environment, the domestic market in fiscal 2006 posted negative growth for the first time in six years. It is very likely that the government will vigorously promote various measures to cut pharmaceutical costs, including annual NHI drug price revision, price reductions that are not based on market prices, and the planned adoption of a scheme for comprehensive medical fees for elderly outpatients. Therefore, the domestic market is forecast to grow only at a modest rate, at around 1-2

• [Qualitative Information, Financial Statements and Other Information] 1. Results of Operations (1) Analysis of Results of Operations 1) Overview of Results In April 2006 the Japanese government carried out a special drug price reduction and revision of price calculation for branded drugs for which substitute generic drugs were available, in addition to the ordinary reduction of National Health Insurance (NHI) drug prices. Furthermore, specific measures to encourage the use of generic drugs began to be implemented. In this severe environment, the domestic market in fiscal 2006 posted negative growth for the first time in six years. It is very likely that the government will vigorously promote various measures to cut pharmaceutical costs, including annual NHI drug price revision, price reductions that are not based on market prices, and the planned adoption of a scheme for comprehensive medical fees for elderly outpatients. Therefore, the domestic market is forecast to grow only at a modest rate, at around 1-2

Pages:[1] [2] [3]   Next